Press, Press Release

Implicity CEO Selected to Participate in HRX 2023 Panel Discussion on AI

Implicity CEO Selected to Participate in HRX 2023 Panel Discussion on AI Cambridge, Mass., September 18, 2023 – Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA. The discussion, AI-aided Remote Interventions – Will this Transform Healthcare Delivery & Outcomes, takes place September 22, 2023, at 2:30 pm (PDT). As part of the discussion, Dr. Rosier intends to share insights on new international recommendations for remote monitoring of cardiovascular implantable devices (CIED) released at Heart Rhythm 2023 (HRS). The expert consensus validated the benefits of using third-party service and solution providers, such as Implicity, to ensure the highest standard of remote monitoring and improve patient outcomes. “We recently published groundbreaking data that demonstrated our AI-powered cardiac remote monitoring technology saves lives and significantly improves health outcomes,” said Dr. Rosier, Electrophysiologist, CEO, and co-founder of Implicity. “I’m eager to join experts on this panel to explore key takeaways from the research and discuss how intelligent technologies can impact our healthcare system for the better now and into the future.” Research unveiled at Heart Rhythm 2023 and led by Dr. Niraj Varma, a Professor of Medicine and consultant Electrophysiologist at the Cleveland Clinic, found patients monitored with Implicity’s alert-based platform experienced a remarkable 22% relative improvement in all-cause mortality compared to conventional RM methods. In addition to taking part in the panel presentation, Implicity also plans to exhibit at the HRX 2023 event (Booth #704) to showcase its latest innovations and technology advancements. The remote monitoring platform incorporates AI and machine learning to enable fast and effective analysis and reporting of patient results collected by CIEDs. About Implicity Implicity is a digital MedTech software company that provides the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, Ph.D., the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants. Implicity’s platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com * Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes. For more information or to schedule a meeting, visit Implicity

Editorial, Press

Leveraging Emerging Science to Improve Patient Outcomes and Streamline Workflow

Leveraging Emerging Science to Improve Patient Outcomes and Streamline Workflow A new scientific study, led by Dr. Niraj Varma and conducted by a team of leading experts, has cemented the importance of remote cardiac monitoring for Cardiac Implantable Electronic Devices (CIEDs). Published in Europace 2023, the paper « Remote monitoring of cardiac implantable electronic devices and disease management » outlines the remarkable benefits in clinical efficiency and patient safety, offering illuminating insights that underscore the value proposition of Implicity’s remote cardiac monitoring platforms. Dynamic and Tailored Patient Treatment Pathways The study underlines the transformative impact of remote monitoring in facilitating personalized, dynamic treatment pathways. This is particularly beneficial for assessing the success rates of Atrial Fibrillation (AF) therapies, a capability that resonates with Implicity’s mission to improve patient outcomes. Our AF Alert Management Algorithm, a CE-marked tool, works seamlessly with the device data and clinical information to offer tailored AF treatment. Enhancements in AF Detection and Anticoagulation Treatment The study impressively demonstrates that algorithms designed to scan all CIED transmissions for AF, enhanced AF detection sensitivity by 10%. In addition, these algorithms also improved the optimal treatment of oral anticoagulation by 6%. Implicity’s AF Alert Management Algorithm directly addresses these findings, focusing on analyzing device data like atrial burden raw data and clinical information such as anticoagulant medications. Our advanced algorithmic approach filters out irrelevant alerts while activating smart alerts for significant changes in AF treatment, streamlining anticoagulation treatment. Efficient Alert Management and Workflow OptimizationAn especially compelling point in the study is the application of an AI tool to filter AF alerts, resulting in an 84% reduction in notification burden without compromising patient safety. The work-saving benefit aligns closely with the capabilities of Implicity’s AF Alert Management Algorithm, which automates the labor-intensive process of AF monitoring.  Assisting Resource-Strained Hospitals The study suggests that third-party resources offer valuable support for healthcare institutions lacking the required staffing. Remote cardiac monitoring from Implicity extends your healthcare team and enables you to focus on critical cases by automating routine tasks. The landscape of cardiac care is undergoing a profound transformation, as illustrated by the study’s conclusion, even though remote monitoring of CIEDs has been the standard of care since 2015. New guidelines suggest clinically stable patients may only require in-office visits every 24 months or less frequently, introducing vast implications for workflow, reimbursement, and data management. The value of Implicity’s remote cardiac monitoring platforms extends beyond the technology’s robustness to the system’s adaptability and scalability. Drawing from the compelling evidence in this latest study, Implicity’s AF Alert Algorithm is a paragon of innovation optimized for efficiency and patient safety. Written by: Megan Grosz Read the Study References Niraj Varma, Frieder Braunschweig, Haran Burri, Gerhard Hindricks, Dominik Linz, Yoav Michowitz, Renato Pietro Ricci, and Jens Cosedis Nielsen. Remote monitoring of cardiac implantable electronic devices and disease management. Europace (2023) 25, 1–11 https://doi.org/10.1093/europace/euad233

Contributed Article, Press

PSQH Interviews Implicity CEO and Electrophysiologist, Arnaud Rosier MD

PSQH Interviews Implicity CEO and Electrophysiologist, Arnaud Rosier MD A new clinical trial on remote monitoring found that while all patients involved saw improved survival rates, the type of remote monitoring had a significant impact. Implicity, a developer of alert-based remote monitoring solutions, in collaboration with the Health Data Hub, looked at a database of over 68,000 patients linking real-world data from patients with cardiac-implantable electronic devices (CIED) to remote monitoring methods and compared mortality rates, annual hospitalizations, and the cumulative duration of hospital stays. The results demonstrated that alert-based monitoring using Implicity’s platform was associated with greater performance compared to historical manufacturer solutions. “We always say remote monitoring is better, but the reality is when it comes to science and evidence, there are not that many examples of proven clinical evidence of better outcomes with remote monitoring,” says Arnaud Rosier, CEO of Implicity. Remote monitoring of cardiac implants (such as connected pacemakers) is a niche area, Rosier says, and thus, there are few studies looking at how remote monitoring for cardiac care impacts mortality, rehospitalization, and cost reduction. “As a physician, I and my colleagues know the value of remote monitoring. If you’re using a pacemaker and not being remotely monitored, your care is probably not being handled well by your physician,” says Rosier. The study was in part intended to bridge the gap in proving the value of this type of monitoring. It wanted to examine not just the monitoring itself, but how the software used for that monitoring played into patient outcomes. One of the reasons to look at remote monitoring for cardiac care now is the opportunity to decrease the burden. “Fifteen years ago, it was a burden—we knew it was beneficial, but it was such a pain to manage all the information coming through. The industry wasn’t organized to triage all the data coming in,” says Rosier. “It’s not what we were trained to do as physicians.” Read the full article here.  

Editorial, Press

Alert-Based Remote Monitoring for CIED Patients

Alert-Based Remote Monitoring for CIED Patients Since the 2015 Heart Rhythm Society’s expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices, remote monitoring for patients with (CIEDs) has been recognized as the gold standard.1 Connectivity became even more crucial during the Covid 19 pandemic, necessitating social distancing and limited in-person interactions; remote patient care had to shift from an optional, convenient solution to an essential requirement in ensuring continuous and effective healthcare provision.2 Though the pandemic may be behind us, remote monitoring continues to benefit clinics with device patients. Nearly ten years have passed since the release of the consensus in 2015. During this time, further research has reinforced the evidence that supports the benefits of remote monitoring to patients and providers. As a result, an updated statement has been issued recommending the implementation of third-party alert-based remote monitoring as part of the care provided to patients with cardiac implants.3 With only a small percentage (6.6%) of remote monitoring transmissions resulting in clinical action, this guideline was a welcomed addition, as most individual transmissions may not be crucial for immediate patient care and can easily overload providers with non-critical data.4 The biggest offender of non-critical transmissions from CIEDs is those of ILRS. A 2018-2019 study analyzed 26,713 consecutive patients equipped with Cardiac Implantable Electronic Devices (CIEDs); 18.8% had an implantable loop recorder (ILR). Of the 82,797 alerts sent, ILRs were responsible for a substantial 50.1%, demonstrating their significant role in the total alert volume. The staggering volume of transmissions and increasing alerts originating from ILRs underscore the necessity for a novel strategy in managing remote monitoring. This is crucial to decrease the time expended by clinical personnel in handling data that does not necessitate any clinical intervention.5 Due to this growing need, sophisticated remote cardiac monitoring (RCM) solutions have progressed from reporting generalized device transmissions to pertinent, actionable alerts. Alert-based monitoring digitally filters patient information, eliminating the deluge of data that comes with reporting on every transmission, regardless of severity to the patient. This approach to remote monitoring expends fewer clinic resources and provides a greater yield of actionable interventions.6 Continuous connectivity and clinic visits go hand in hand, with the latter done sparingly and when specific, actionable events are detected. This approach enhances the efficiency and responsiveness of patient care, ensuring timely medical intervention when necessary. Emerging as a leader in alert-based remote monitoring, Implicity’s intuitive cloud-based software enables healthcare providers to receive immediate alerts regarding any changes in patient conditions, thereby reducing the latency between the occurrence of a health event and its detection. By integrating directly with the manufacturer’s portals, the AI-powered solution ensures that pertinent data is readily accessible, enabling swift, data-driven decisions. This proactive approach to patient care fosters enhanced clinical outcomes, improves patient safety, and optimizes healthcare delivery by providing critical information as soon as it becomes available. Alert-based RCM not only benefits patients but also greatly improves the efficiency of device clinics. In the past, patients with CIEDs needed to visit clinics for check-ups regularly. This often meant taking time off work, waiting longer for appointments, and risking delayed detection of device-related problems. With alert-based RCM, device clinics can optimize workflow and streamline patient management. The constant remote monitoring of CIEDs ensures that clinics receive relevant data, eliminating unnecessary clinic visits. This enables healthcare providers to focus on patients requiring immediate intervention, enhancing overall clinic efficiency and providing better patient care. Patient connectivity is a key success factor of alert-based RCM, as it is a prerequisite for quick alert transmission. The 2023 Heart Rhythm Society’s expert consensus statement highlighted the importance of device clinics in managing patient connectivity. By identifying disconnected patients and automatically sending them an SMS, platforms like Implicity reduce the connectivity management effort for device teams while improving patient compliance. RCM solutions such as Implicity integrate seamlessly with existing healthcare systems, providing intuitive interfaces for clinicians and reducing the data management burden. By leveraging these resources, device clinics can allocate their resources effectively, providing personalized care to patients needing it while reducing the strain on the healthcare system. The advent of alert-based RCM systems has transformed the landscape of remote cardiac monitoring for patients with CIEDs and those who care for them. Third-party resources have emerged as invaluable tools for enhancing patient care and optimizing device clinic efficiency. By continuously monitoring crucial cardiac parameters and automatically alerting healthcare providers of abnormalities, alert-based remote monitoring can help ensure prompt intervention, reducing the risk of complications and hospital readmissions by up to 4%.7 By: Megan Grosz 1Slotwiner, Varma, et al. 2015 HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Published: May 13, 2015DOI:https://doi.org/10.1016/j.hrthm.2015.05.0082Varma N, Marrouche NF, Aguinaga L, et al. HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. J Am Coll Cardiol. 2020;76(11):1363-1374. doi:10.1016/j.jacc.2020.06.0193Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez-Cabanillas N, Abe H, Boveda S, Chew DS, Choi JI, Dagres N, Dalal AS, Dechert BE, Frazier-Mills CG, Gilbert O, Han JK, Hewit S, Kneeland C, Mirza SD, Mittal S, Ricci RP, Runte M, Sinclair S, Alkmim-Teixeira R, Vandenberk B, Varma N; Document Reviewers; Davenport E, Freedenberg V, Glotzer TV, Huang JL, Ikeda T, Kramer DB, Lin D, Rojel-Martínez U, Stühlinger M, Varosy PD. 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic. J Arrhythm. 2023 May 19;39(3):250-302. doi: 10.1002/joa3.12851. PMID: 37324757; PMCID: PMC10264760.4Varma N, Epstein AE, Irimpen A, Schweikert R, Love C; TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation. 2010;122(4):325-332. doi:10.1161/CIRCULATIONAHA.110.9374095O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote Monitoring Alert Burden: An Analysis of Transmission in >26,000 Patients. JACC Clin Electrophysiol. 2021;7(2):226-234. doi:10.1016/j.jacep.2020.08.0296Varma N, Love CJ, Michalski J, Epstein AE; TRUST Investigators. Alert-Based ICD Follow-Up: A Model of Digitally Driven Remote Patient Monitoring. JACC Clin Electrophysiol. 2021;7(8):976-987. doi:10.1016/j.jacep.2021.01.0087N, Marijon E, Abraham A, Ibnouhsein I, Bonnet J-L, Rosier A, Singh Heart Rhythm

Press

Reality versus Rhetoric in Healthcare AI Marketing

Reality versus Rhetoric in Healthcare AI Marketing Transparency and Compliance in Healthcare AI is Crucial In recent years, the advent of artificial intelligence (AI) and machine learning (ML) in healthcare has changed the landscape in how we diagnose, treat, and manage medical conditions. At Implicity, we’ve been at the forefront of this transformation, continually developing and marketing AI-enabled medical devices that improve patient outcomes and streamline healthcare processes.  However, as the use of AI and ML in healthcare grows, the challenge of marketing these innovations responsibly becomes crucial. A recent systematic review in the field highlighted an interesting finding – not all marketed claims about AI- and ML-enabled devices align perfectly with their FDA clearances.  This revelation underscores the vital importance of upholding integrity and compliance in marketing these advanced technologies. At Implicity, we’re committed to being transparent and maintaining regulatory compliance, firmly standing among those organizations that ensure their marketing claims match their FDA-approved capabilities. This is essential for regulatory adherence and fostering and sustaining trust in our innovative products. In response to the aforementioned research, we want to assure our customers and partners that Implicity is committed to upholding the highest ethical marketing standards. Each claim we make about our AI-enabled medical devices is thoroughly vetted and backed by FDA-approved capabilities outlined in our 510(k) clearances. We are proud to be part of the 80.6% of consistent devices, a testament to our dedication to regulatory compliance. At Implicity, we understand that the intersection of AI and healthcare is not just about technology. It’s about trust, honesty, and responsibility. Our commitment to these values means that when you choose Implicity, you choose a partner that provides cutting-edge technology and guarantees transparency, regulatory compliance, and the highest ethical standards. This is our promise to you. 

Editorial, Press

Harnessing AI to Combat the Data Deluge from Implantable Loop Recorders

Harnessing AI to Combat the Data Deluge from Implantable Loop Recorders The Intersection of AI and Remote Monitoring in Reducing Alert Burden is a Critical Path Forward in Cardiac Care. In the realm of cardiac healthcare, the role of remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) is pivotal. However, the vast array of alerts generated by these devices poses a significant challenge to the effective and efficient management of cardiac patient care. A multicenter study examining the remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) has emphasized the significant alert burden associated with these devices. Over 82,000 alerts were generated over a 12-month period involving 26,713 patients, with implantable loop recorders (ILRs) notably overrepresented in these alert numbers.1 ILRs, often used for extended cardiac event monitoring, were responsible for over half of the total alerts. This disproportionate contribution may be due to the sensitivity of ILRs in capturing subclinical arrhythmias and the high frequency of recorded events. However, addressing the alert burden, particularly the volume generated by ILRs, requires efficient, intelligent solutions. One such solution comes from Implicity’s proprietary artificial intelligence algorithm: the ILR ECG Analyzer. This software medical device has been specifically designed to reduce the number of false positives in ECG recordings from patients implanted with Medtronic ILRs. Data shows that the ILR ECG Analyzer reduces the number of false positives by an impressive 79% while maintaining a high sensitivity of 99%. By effectively filtering out a significant portion of non-urgent or non-actionable alerts, this technology allows healthcare providers to better focus their attention and resources on truly critical patient and device events.2 In addition to improving the efficiency of RM, this reduction in alert burden can also potentially lead to better patient outcomes. As such, the ILR ECG Analyzer is a practical and beneficial application of AI in the healthcare technology sector, aligning with the broader scientific goal of optimizing the management and understanding of data generated through remote cardiac monitoring systems. By: Megan Grosz 1O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote Monitoring Alert Burden: An Analysis of Transmission in >26,000 Patients. JACC Clin Electrophysiol. 2021;7(2):226-234. doi:10.1016/j.jacep.2020.08.0292https://academic.oup.com/eurheartj/article/42/Supplement_1/ehab724.0316/6393406?login=true Download PDF

Press

Seamless Data Collection and Transmission

Seamless Data Collection and Transmission Transform your device clinic with automated data collection and seamless integration. Designed to streamline the collection and transmission of in-clinic data, InLink is a smart tool that automatically collects patient device data – including PDF files and raw data from devices of all manufacturers – during in-clinic visits. Without the need for manual input or USB drives, the data is transmitted swiftly and securely to the Implicity SaaS remote monitoring platform. Once processed, the data is assigned to the appropriate patient, with reports easily generated from the raw data with manufacturer PDFs also conveniently accessible at the end of each patient report. The Benefits of InLink By integrating InLink into your data management process, you stand to gain the following benefits: Secure Data Transmission: Ensures the safe transfer of data from the programmer to the Implicity platform, upholding patient confidentiality and data integrity. Effortless Data Collection: Eliminates the manual collection of in-clinic data. InLink makes gathering PDF files and raw data a simple task. Immediate Transmission: Data transmission happens in a snap, eliminating delays in data transfer. Automated Report Generation: Facilitates the effortless creation of in-clinic reports from raw data, saving time and improving accuracy. Easy Access to Manufacturer PDFs: Manufacturers PDFs are readily available for review or reference at the end of each patient report. Adopt InLink and enhance the efficiency and reliability of your in-clinic data management, leaving you more time to focus on what really matters.

Editorial, Press

From Data to Discovery: Remote Monitoring’s Critical Role in Research

From Data to Discovery: Remote Monitoring’s Critical Role in Research Data-driven insights from cardiac implantable electronic devices (CIEDs) can revolutionize research, leading to transformative discoveries in the healthcare field. In the ever-evolving healthcare field, the ability to collect and analyze data is paramount for healthcare providers and researchers. Cardiac implantable electronic devices (CIEDs) are vital in monitoring patients with cardiac conditions. Leveraging remote monitoring (RM) to harness the vast amounts of data generated by these devices offer benefits that are far-reaching. In addition to improving safety for the individual patient, RM is a powerful research tool that can deliver information from an enormous number of patients, providing the scientific community with important data regarding cardiac events safety.1 By collaborating with third-party remote monitoring platforms, researchers and clinicians can explore numerous research fields with greater precision and depth. They can investigate the efficacy of different treatment strategies, identify factors contributing to adverse events, and develop innovative interventions tailored to individual patients. For instance, through advanced data analytics, Implicity’s platform can identify various changes in a patient’s heart status, facilitating early detection of potential complications and timely interventions. Remote monitoring solutions like that offered by Implicity help to address the growing need to harness complex CIED data for clinical research by aggregating it into useful, actionable information for researchers. Raw Data for ResearchAccessing automatically synced raw data from CIEDs eliminates the need for manual data extraction and provides researchers with unprecedented immediacy in data availability. By obtaining raw data from CIEDs, healthcare providers can delve into the intricacies of device performance, patient-specific parameters, and other vital information. This access to data enables quick identification of trends, anomalies, and patterns, ultimately leading to timely interventions and improved patient outcomes. Normalized Patient Data Across ManufacturersOne of the challenges in cardiac research is the heterogeneity of CIEDs produced by different manufacturers. Each manufacturer may use proprietary data formats and structures, making comparing and analyzing data across different devices difficult. Implicity overcomes this hurdle by normalizing patient data across various CIED manufacturers. Harmonizing the data allows researchers to seamlessly compare and combine datasets for comprehensive analysis. This unified approach to data integration promotes collaboration, facilitates larger sample sizes, and enhances the statistical power of research studies. Customized Electronic Case Report Forms (eCRFs)The Implicity research feature provides customized electronic Case Report Forms (eCRFs) to facilitate data collection for research purposes. These eCRFs can be tailored to specific research protocols, ensuring standardized data collection across multiple sites. By streamlining data collection processes, the tool minimizes errors, enhances data quality, and simplifies data analysis. Researchers can easily capture the required variables, monitor study progress, and adjust and optimize data collection efficiency. Patient Consent TrackingRespecting patient privacy and ensuring informed consent is crucial in any research endeavor. Implicity incorporates a patient consent tracking feature that enables healthcare providers to manage and monitor patient consent in real-time. This ensures compliance with ethical and legal requirements, provides transparency to patients, and protects their rights. Researchers can easily track and manage consent status throughout the study, ensuring the privacy and autonomy of study participants. Leveraging data from CIEDs is crucial in advancing cardiac research. Partnering with platforms like Implicity opens new doors for exploring research fields, conducting clinical studies, and ultimately improving patient outcomes. By: Megan Grosz 1Lappegård KT, Moe F. Remote Monitoring of CIEDs-For Both Safety, Economy and Convenience? Int J Environ Res Public Health. 2021 Dec 28;19(1):312. doi: 10.3390/ijerph19010312. PMID: 35010572; PMCID: PMC8751026. Download PDF

Contributed Article, Press

Building an Effective Hybrid Practice

Building an Effective Hybrid Practice Telemedicine is here to stay. But that doesn’t mean that in-person healthcare is going anywhere – soon or ever. It’s becoming clear that a hybrid approach is the way forward for the healthcare sector, with many hospitals and clinics already relying on remote technologies that they scaled up dramatically during the COVID-19 pandemic. As a result of that experience, previously reluctant clinicians and patients have grown accustomed to telemedicine solutions, and reimbursement policies have begun to catch up with the technology. Telemedicine visits and remote patient monitoring (RPM) expand access to care, help alleviate the challenges associated with provider shortages, and in many instances, are more convenient for patients. While alternatively, in-person care is sometimes preferred (and often necessary) for specific patients, tests, and treatments. Much of the technology needed to provide excellent hybrid care is already here, but healthcare organizations are still struggling to effectively stitch solutions together in ways that lead to both manageable workflows and improved outcomes. Highlighted below are three areas that providers and administrators should focus on as they build out their hybrid healthcare offerings. 1. Systems Integration – Presently, some telemedicine and remote monitoring solutions exist essentially as islands: They offer important use cases and information on their own, but because they’re not effectively integrated with other IT systems, they are limited in what they can add to a patient’s overall treatment plan. This is going to have to change – and change quickly. In fact, I would go so far as to say that integration with electronic health record (EHR) systems like Epic has become imperative for remote monitoring tools. The obvious examples include having two-way communications of documents and relevant data from the EHR to additional remote monitoring platforms, but also having billing information generated by specialized algorithms flowing to the proper users. Integrations with EHR systems can offer a whole new level of benefits. One simple, but powerful, example: by marrying clinical data with data from cardiac remote monitoring (CRM) devices to classify and prioritize alerts automatically. Specifically, being able to feed a clinical decision support system with data about medication can help automate triaging alerts and thus considerably decreases how much noise has to be reviewed by hand. Systems integration doesn’t have to happen all at once. A healthcare organization might work its way up through identity verification, automated billing, and integrated reports, all the way to two-way sync and direct access. Read the full article here. By Arnaud Rosier, CEO of Implicity